Aduro BioTech (NASDAQ:ADRO) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.20) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.03, Fidelity Earnings reports. Aduro BioTech had a negative net margin of 624.51% and a negative return on equity of 68.69%. The firm had revenue of $4.80 million for the quarter, compared to analyst estimates of $4.55 million.
Shares of ADRO traded up $0.11 during mid-day trading on Friday, reaching $1.18. 2,944,800 shares of the stock traded hands, compared to its average volume of 562,635. The firm has a market cap of $91.36 million, a price-to-earnings ratio of -1.02 and a beta of 1.48. The stock has a fifty day simple moving average of $1.05 and a 200 day simple moving average of $1.80. Aduro BioTech has a 12-month low of $0.90 and a 12-month high of $4.59. The company has a quick ratio of 8.45, a current ratio of 8.45 and a debt-to-equity ratio of 0.32.
In other news, CEO Stephen T. Isaacs sold 31,098 shares of Aduro BioTech stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $1.31, for a total transaction of $40,738.38. Following the sale, the chief executive officer now owns 295,926 shares in the company, valued at $387,663.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 52,185 shares of company stock worth $68,362 in the last quarter. Insiders own 5.20% of the company’s stock.
Several research analysts recently commented on the stock. Cowen restated a “buy” rating on shares of Aduro BioTech in a report on Friday, August 2nd. ValuEngine upgraded shares of Aduro BioTech from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $8.01.
Aduro BioTech Company Profile
Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.
Further Reading: What causes a recession?
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.